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[1]
Cellular Response to Irradiation in Carriers 
of BRCA1 and BRCA2 Mutations 
Barwell J., Pangon L., Sodha N., Georgiou A., Kesterton I.,
Langman C., Green P., Morris J.R., Solomon E., Berg J.,
Docherty Z., Camplejohn R., Eeles R., Hodgson S.V.
It is not known whether individuals who are
heterozygous for germline BRCA1 and BRCA2 mutations
have an altered cellular response to irradiation. We have
investigated 53 BRCA1 and BRCA2 mutation carriers
who have never had a malignancy and age-matched
unaffected controls.
We found that peripheral blood lymphocytes from
BRCA1 and BRCA2 mutation carriers have normal cell
cycle kinetics and apoptotic response to irradiation
compared with age-matched unaffected controls.
However, we detected an increased number of
chromosome breaks post irradiation using the G2
assay (P=0.002) and the S phase enrichment assay
(P=0.011) in BRCA1 mutation carriers compared with
age-matched controls. BRCA2 mutation carriers also
had an increased number of chromosome breaks per
cell compared to their matched controls using the S
phase enrichment assay (P=0.045).  
In an attempt to identify a cause for this altered
cellular response to irradiation, the gene expression
profiles of peripheral blood lymphocytes from five
BRCA1, five BRCA2 and five age-matched controls pre
and post irradiation were measured using human
U133 Plus 2.0 arrays. BRCA1 expression in BRCA1
mutation carriers compared with the age-matched
controls was reduced by 43% compared with controls
(p=0.038) post 2Gy and by 41% post mock treatment
(p=0.032). There was a non-significant reduction in
BRCA2 protein expression post irradiation in BRCA2
mutation carriers of 34% compared with controls
(p=0.24). We detected a number of consistently altered
genes in response to irradiation in mutation carriers
with BRCA1 or BRCA2 haploinsufficiency and discuss
the functional implications of these.
[2]
Flow Chart for Cancer Genetics Studies at St George’s Hospital
Barwell J., Njindou A., Bancroft E., Eeles R., Saggar A.
Clinical trials are legion and often overlap or have
competing interests. We at St George’s Hospital have
devised a flow chart for Cancer Genetics to ensure that
patients have the greatest opportunity to be involved
in appropriate research studies. This has helped clarify
entry and exclusion criteria for various studies and
improved overall recruitment.
The flowcharts (Figures 1-4) include the following
studies: EMBRACE, IMPACT, POSH, PROSE,
UKFOCSS, POETS (Mirena coil study), CARBOPLATIN
BRCA TRIAL, IBISII, FABCC, BRCA3, SIB PAIR,
EUROPAC, FH01 and CORGI. This can be easily
tailored for other centres with a different selection of
studies. Copies can be collected from Dr Julian Barwell.
Cancer Genetics Group Spring Meeting
22 & 23 May, 2006
Birmingham, U.K.
Introduction
The Cancer Genetics Group (CGG) is a British multidisciplinary organisation. The purpose of the CGG is to
improve the quality of care of patients and their families with any condition resulting in hereditary tumours.
Eligible members are those with an interest in hereditary predisposition to cancer including clinicians, counsellors
and scientists. Membership is affiliated through the British Society of Human Genetics. At least one scientific
meeting of the CGG is held every year. Normally there is a two-day spring meeting at a host city in the UK and
a single day winter meeting in London. More information on the CGG can be found on the CGG web site
www.srl.cam.ac.uk/cggwebsite/cgg.htm
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Study where mutation identified
PROSE
Prevention and Observation of Surgical Endpoints
An estimation of breast and ovarian cancer risk reduction after
the use of
risk-reduction surgery and to evaluate psychosocial endpoints in
women who carry BRCA1 and BRCA2 mutations.
POSH
Prospective Outcomes in Sporadic Vs Hereditary breast cancer.
A prospective, case-controlled, observational study of treatment
choices and outcomes in young women with breast cancer
CARBOPLATIN/DOCETAXEL
A chemotherapy trial in relapsed breast cancer patients.
EMBRACE
EpideMiological Study of Familial BReast CAnCEr in BRCA1 and
BRCA2 mutation carriers
IMPACT
Identification of Men with a genetic predisposition to ProstAte
Cancer
POET
Prevention Of Endometrial Tumours study
The use of a progesterone releasing intra-uterine device (Mirena
coil) in women with HNPCC at high risk of developing
endometrial tumours.
CAPP-Colorectal Adenomas/carcinoma Prevention Programme
for proven HNPCC mutation carriers 




UK Familial Ovarian Cancer Screening Study
Evaluation of ovarian screening in primary relatives of affected
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[3]
Lay and Professional Understanding of Cancer Genetics Activities in the UK
Cooke S., Crawford G., Lucassen A., Parker M., Hallowell N.
In the UK, DNA testing for hereditary cancers and
high-risk cancer surveillance takes place either as part
of research protocols (and thus requires ethical
approval) or is offered as an NHS clinical service. The
route chosen may depend on arbitrary factors. There
is a need to determine the impact that current research
governance arrangements have on research and
clinical practice in cancer genetics. This multidisciplinary
project investigates healthcare professionals’, patients’
and regulators’ understanding of cancer genetics
activities within the UK. It looks at how these groups
conceive of the research-clinical practice distinction,
and aims to identify any perceived ambiguities and
practical and/or ethical problems that are generated
for the different actors. Semi-structured interviews
(n=100) are currently being carried out with 3 groups:
healthcare professionals who are involved in cancer
genetics research and/or provide a clinical cancer
genetics service/refer patients to such a service; patients
involved in cancer genetics research (DNA and or
clinical studies) and regulators who play a role in the
regulation of clinical research or clinical practice. 
Fig. 2. [2]
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[4]
Penetrance Estimates for BRCA1 and BRCA2 Based on Genetic Testing
in the Service Setting
Evans D.G.1, Shenton A.1, Woodward E.2, 
Lalloo F.1, Maher E.R.2
1Academic Unit of Medical Genetics and Regional Genetics Service, St Mary’s Hospital
Manchester M13 0JH, UK; 2Division Section of Medical and Molecular Genetics, University
of Birmingham School of Medicine, and West Midlands Regional Genetics Service,
Birmingham, UKz
Background: The identification of a BRCA1 or
BRCA2 mutation in a familial breast cancer kindred
allows genetic testing of at-risk relatives. However,
considerable controversy exists regarding the cancer
risks in women who test positive for the family
mutation. 
Methods: We reviewed 385 unrelated families (223
with BRCA1 and 162 with BRCA2 mutations)
ascertained through two regional cancer genetics
services. We estimated the penetrance for both breast
and ovarian cancer for female mutation carriers (904
proven mutation carriers – 1442 females in total
Contact
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Study
IBIS II
An international multicentre study of Anastrozole vs Placebo in
Postmenopausal Women at Increased Risk of Breast Cancer and
An international multicentre study of Anastrozole vs Tamoxifen in
Postmenopausal Women with DCIS
FABCC
Familial Association in Breast Cancer Collaboration
Identification of breast cancer susceptibility genes
FHO1
Comparison in mortality rates in women with breast cancer under
the 50 with a significant FH. Women having regular
mammography compared to those not being screened.
EUROPAC
The EUROpean Registry of Hereditary PAnCreatic Diseases 
Gene identification, risk factors and screening protocol consensus
CORGI
COloRectal tumour Gene Identification study.
The collection of families with multiple cases of colorectal
neoplasia to identify novel predisposition genes through linkage
and association using familial cases.
The Genetics of Familial Breast Cancer Study (BRCA3)
To identify and characterise genes that predispose to breast
cancer in families with three or more cases of breast or ovarian
cancer
SIB PAIR STUDY
Breast cancer susceptibility gene identification in female sib-pairs
where no cases or ovarian cancer are present in family.
UKFOCSS
UK Familial Ovarian Cancer Screening Study
Evaluation of ovarian screening in primary relatives of affected
member of high risk families.
UKGPC 
UK Genetic Prostate Cancer Study (Open to 2012)
To identify susceptibility genes and study gene-environment
interactions
Fig. 4. [2]
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assumed to carry the mutation) and also assessed the
effect of mutation position and birth cohort.
Results: Breast cancer penetrance to 70 and 80
years was 75% (95%CI 72.5-77.5%) and 85% (95%CI
82.4-87.6%) respectively for BRCA1 and 80% (95%CI
77.6-82.4%) and 90% (95%CI 87.4-92.6%) for
BRCA2. Ovarian cancer risk to 70 and 80 years was
60% (95%CI 65-71%) and 65% (95%CI 75-84%) for
BRCA1 and 30% (95%CI 25.5-34.5%) and 37%
(95%CI 31.5-42.5%) for BRCA2. These risks were only
marginally reduced by excluding the index case from
each family. We found evidence of a strong cohort
effect with women born after 1960 having a cumulative
risk of 40% for breast cancer by 40 years of age
compared to <10% in women born before 1930.
Conclusion: In high-risk families, women who test
positive for the familial BRCA1/BRCA2 mutation are
likely to have cumulative breast cancer risks in keeping
with the original estimates obtained from such families.
This is particularly true for women born after 1960.
[5]
Study Comparing Two Types of Screening Provision for People with von
Hippel-Lindau Disease
Fraser L.1, Watts S.2, Cargill A.3, Sutton S.4, Hodgson S.1
1Department of Medical & Molecular Genetics, Guy’s Hospital, London, UK; 2Department of
Clinical Genetics, Guy’s Hospital, London, UK; 3Cancer Research UK, Medical Statistics Group,
Oxford, UK; 4Department of Public Health and Primary Care, University of Cambridge, UK
Purpose: Patients diagnosed with von Hippel-Lindau
(VHL) disease require life-long surveillance for clinical
manifestations of this multi-system disease. This descriptive
study reports on two types of screening provision for VHL
patients in the UK: single appointment One Stop clinics
and multiple appointment Ad Hoc clinics. 
Methods: One hundred and seventeen VHL patients
from eight regional genetics centres were approached
to take part. Seventy-two (61.5%) returned a completed
study questionnaire. Fifty-four (75%) were screened at
One Stop clinics. Comprehensiveness of surveillance,
attendance rates, patient ratings of quality of care and
levels of psychological morbidity were compared
between the two types of service. 
Results: One Stop clinics provided a more
comprehensive screening service evidenced by double
the number of site-specific examinations reported at Ad
Hoc clinics. More patients at One Stop clinics attended
regularly. There was no difference in patient ratings of
quality of care between the two types of service. While
levels of disease severity were similar between the two
groups, a greater proportion of those screened at One
Stop clinics were classified as anxious or depressed.  
Conclusion: The study findings suggest that an
optimum screening service for VHL patients is one
based on One Stop clinics offering comprehensive
surveillance and psychological support.
[6]
Gene-Related Cancer Spectrum in Families with Lynch Syndrome
Geary J.1, Sasieni P.2, Hodgson S.1
1Department of Medical Genetics, St George’s University of London, Cranmer Terrace,
London, SW17 0RE, UK; 2Cancer Research UK Department of Epidemiology, Mathematics
& Statistics, Cancer Research UK Clinical Centre at Barts and The London, Wolfson Institute
of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, UK
We obtained cancer details and age at diagnosis in
mutation carriers and their 1st and 2nd degree relatives
in a cohort of 132 families with Lynch Syndrome and




























Fig. 1. Breast cancer cumulative incidence by gene (BRCA1 or
BRCA2)
one minus survival functions
Hereditary Cancer in Clinical Practice 2006; 4(3) 159
Abstracts
Table 1. [6] Relative risk and odds ratios of cancers seen in HNPCC families 
Tumour Type Number of Cancers Familial Relative Risk Odds Ratio
MLH1 MSH2 MSH6 total MLH1 MSH2 total MLH1 MSH2 total
colorectal 301 262 14 577 – – – 36.0 44.1 36.9
colorectal <40 years 71 58 1 130 *2.2 0.8 1.3 500.4 575.3 490.3
non-colorectal <40 22 24 2 48 2.1 1.0 1.3 4.6 7.1 5.4
endometrial 39 58 9 106 *2.7 ***5.6 ***3.6 25.3 52.9 36.7
gastric 25 25 3 53 1.2 *2.7 1.5 10.0 14.1 11.4
breast 21 16 2 39 1.2 0.4 0.7 1.7 1.8 1.7
renal 5 30 2 37 – ***7.4 ***4.3 2.9 24.6 11.6
ureter 0 13 0 13 – **9.9 – 0.0 292.9 111.4
bladder 4 9 0 13 16.8 2.0 3.7 1.0 3.1 1.7
ovary 8 19 0 27 0.0 2.3 1.7 3.9 13.0 7.0
pancreas 12 9 1 22 *5.7 2.2 *3.8 7.2 7.6 7.1
skin 8 17 1 26 2.7 *4.2 *3.3 – – –
sebaceous adenoma 3 6 0 9 *45.6 *24.4 ***29.0 – – –
sarcoma 4 4 0 8 13.8 ***68.1 ***26.7 7.6 10.7 8.1
small intestine 3 4 0 7 – – – 19.8 37.1 24.7
biliary tract 2 0 0 2 – – – 6.8 0.0 3.6
other 38 27 6 71 – – – 1.0 1.0 1.0
total 470 480 38 988
cancers in Lynch Syndrome families was compared to
that in the general population (RR), Table 1. Colorectal
cancer was the most common site (64% and 55% in
individuals from families with MLH1 or MSH2 mutations
respectively). Mean age at diagnosis in MSH6 families
was 57.7y compared to 42.7y in both MLH1 and
MSH2 mutation families. Endometrial cancer was more
common in MSH2 mutation carriers, RR 53 (25 for
MLH1), and even more common in MSH6 families,
median age at diagnosis 49y. Gastric cancer accounted
for 5% of cancers in both MLH1 and MSH2 mutation
families (RR 12), 53% diagnosed before 50y, 28%
before 40y age, with clustering within MSH2 mutation
families. Seven cases of small intestinal cancer occurred
in MSH2 and MLH1 mutation families (RR 25). Six of
seven families with renal cancer had multiple cases; the
majority were in MSH2 mutation families, and familial
clustering was significant. 19 of 27 ovarian cancers
seen were in MSH2 mutation carriers, 70% diagnosed
before 50y, where age known. There were 9 cases of
sebaceous skin cancer, 3 in two MLH1 and 6 in four
MSH2 mutation families. 14 of 22 cases of pancreatic
cancers seen were known to be diagnosed below 60y,
youngest at 29y. We found only a slightly increased RR
(1.7) of breast cancer, and no familial clustering. 
[7]
Cancer Genetic Services and Consent from Third Parties
Lucassen A., Frayling I. 
Southampton and Cardiff 
Anecdotal reports and an audit of CGG members
in December 04 suggest that gaining access to results
or tissue blocks of deceased relatives for the purposes
of genetic counselling is perceived as increasingly
problematic. Hospital records or pathology
departments often request signatures from third parties
(e.g. nearest relative, spouse, ‘next of kin’). There may
be ethical and/or practical problems in contacting such
third parties who are not patients of genetic services
and have shown no desire to be contacted. Whilst the
Human Tissue Act 2004 has clarified some of these
issues, uncertainties remain. Although this new law is
yet to be enacted, it would seem that access to tissue
blocks of the deceased requires consent to be sought
from a list of qualifying relationships in hierarchical
order. The first two rankings are devoted to individuals
who may not be biological relatives of the deceased
yet they can veto the use of tissue for the benefit of
biological relatives. However, should DNA analysis be
Hereditary Cancer in Clinical Practice 2006; 4(3)160
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performed the list is unranked and anyone in a list of
qualifying relationships can consent. It is not clear
whether this also applies to the handling of a tissue
block in order to extract DNA. The current common
and statute law around access to records and samples
will be discussed highlighting inconsistencies and
suggesting consistent pragmatic approaches.
[8]
Identification of Men with a Genetic Predisposition to Prostate Cancer:
Targeted Screening in BRCA1 and BRCA2 Mutation Carriers and Controls:
the Impact Study
Mitra A.V.1, Bancroft E.K.2, Eeles R.A.1, 2 on behalf of the
Impact Steering Committee
1Institute of Cancer Research, London; 2Royal Marsden Hospital NHS Foundation Trust,
London
Key words: prostate cancer, genetics, screening
This international collaboration aims to conduct the
largest screening study of men with a known genetic
predisposition to prostate cancer. Prostate cancer may
be an indolent disease and screening the general
population is controversial, with no established
reduction in mortality. Mutations in BRCA genes may
increase the relative risk of prostate cancer by up to
23-fold. We aim to establish whether male BRCA1 and
2 mutation carriers indeed have a higher prostate
cancer incidence, are at risk of aggressive prostate
cancer and if a targeted screening programme is
feasible in this population. We will also undertake
proteomic profiling of urine and serum in these men.
Methods
850 tested BRCA1/2 mutation carriers and 850
tested non-carriers will be recruited over 5 years in 39
centres. Annual serum PSA will be taken. If PSA is less
than 3, the test will be repeated the following year. If
the PSA is greater than 3, prostate biopsy will be
offered. In the event of a cancer diagnosis, treatment
will be according to local centre guidelines. Serum,
plasma and urine samples will be taken to investigate
proteomic profiles of these fluids in an attempt to
identify more specific markers for prostate cancer. 
100 men will be recruited by the end of 2006.
Baseline PSAs, prevalence of undiagnosed prostate
cancer, and the age of onset in male BRCA1and 2
mutation carriers will be compared with the control
group. Analysis of proteomic profiles will be established
between BRCA1 and BRCA2 carriers, controls negative
for these mutations and carriers and non-carriers with
a diagnosis of prostate cancer. 
Results (see graphs)
Recruitment started in November 2005; 24 men
have been enrolled, 10 BRCA2 carriers, 8 BRCA1
carriers and 6 controls. One BRCA1 carrier has a PSA
of 3.8 and is currently awaiting a biopsy. All other men
have a PSA less than 3. The one man with a PSA
greater than 3 also has a free total PSA of 11%. In
total, 3 BRCA1 carriers have a free total PSA less than
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[9]
Disseminating BRCA2 Test Results Identified in the Research Context 
to Relatives of Deceased Prostate Cancer Patients: 
a Qualitative Study of Relatives’ Experiences
Ormondroyd E.1, Moynihan C.1, Ardern-Jones A.2, 
Eeles R.1, Davolls S.1, Watson M.2
1Institute of Cancer Research, Sutton, UK; 2Royal Marsden Hospital, Sutton, UK
This study was established as an adjunct to an earlier,
national study at the Royal Marsden Hospital and UK
Institute of Cancer Research, which detected pathogenic
BRCA2 mutations in a number of men diagnosed with
prostate cancer before the age of 55 (Edwards et al.,
2003). The men had died before the results of that study
were available, and the Clinical Genetics team at the
ICR/RMH attempted to contact the next-of-kin, offering
an information/counselling session. 
The current study is a psychosocial evaluation of the
impact of being contacted about the existence of a
genetic fault in a deceased relative. A snowball sampling
strategy has been used to recruit relatives with whom the
next-of-kin has shared this information. We are exploring:
• relatives’ reactions to learning about the genetic test
results in their deceased relative,
• prior and current perceptions of risk, and risk
management decisions,
• communication with other relatives,
• information and support needs,
• whether relatives perceive that they have experienced
benefit or harm as a result.
Participants, some of who have and some have not
elected to have genetic counselling, include partners,
adult children and siblings of the deceased men. Semi-
structured, in-depth interviews with twelve relatives are
currently being analysed using a grounded theory
approach. Findings will be discussed, including the
importance of the role of the communicator, who may
not be the closest relative. Effective communication
and subsequent handling of the information, whether
or not this includes engagement, is dependent on a
positive relationship.
[10]
Grief in Cancer Genetics
Philp C.
East Anglian Medical Genetics Service, Department of Clinical Genetics, Box 134,
Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QQ
A 63-year-old gentleman was seen for HNPCC
predictive testing following the identification of an
MSH2 mutation within the family. Mr A was at 50% risk
of inheriting the familial MSH2 mutation. Mr A had
suffered multiple close bereavements due to cancer in
the family and he had also lost his wife to breast cancer
at the age of 46 years. Mr A arrived at the appointment
keen to have a predictive test to ‘prove he did not have
the gene’. Mr A was from a large cancer family who
were all now being seen for predictive testing. The
family’s anxiety had been heightened by the sudden
loss of a 46-year-old family member to pancreatic
cancer. This case highlights the importance of seeing
each family member as an individual in their own right
and also that their experience of the cancers in the
family will be unique to each of them. There may be
further experiences of cancer outside of the blood
family that the individual has experienced. The case
also shows that cancer within families can heighten
individuals’ awareness of their own mortality, but with
genetic cancer conditions this also links into feelings
of guilt with the realisation of their children’s mortality. 
[11]




This study explores the experiences of women who
have undergone predictive BRCA genetic testing and
received negative (favourable) results. Data were
gathered using questionnaires and semi-structured
interviews from nine women who had undergone
testing during the period 2001-2003.  
The study indicates that for many women, although
their new cancer risk status is understood in terms of
numerical value, the implications of this risk status are
not fully realised. High cancer worry following testing
indicated that a favourable result did not provide
sufficient reassurance. Family experience was
particularly influential in an individual’s risk perception.  
Fear of breast cancer led to requests for
inappropriately frequent breast surveillance but a lack
of breast awareness amongst the women. Whilst
genetic testing was motivated by a desire for control
of the future, genetic testing was only one of many
factors influencing the women’s attitudes to cancer. 
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The findings indicate a need for better education
of women regarding breast awareness and the
rationale behind surveillance practices, as well as
further genetic counselling for women with high cancer
worry irrespective of their test result. Further research
is required to sample a greater number of women.




The last few December CGG meetings have seen a
dedicated slot for the discussion of interesting and/or
difficult cases. This has proved highly popular with the
membership and all of the 130 or so members present
at the December 2005 meeting voted for its continuance
and also inclusion at the summer CGG meetings. The
1.5-2 hour slot was designed to facilitate more informal
discussion than possible in the scheduled talks and
plenaries. We asked for any cases with ongoing
management problems, clinical queries, ethical or legal
dimensions or just learning points. This broad remit allows
a variety of cases to be discussed, allowing members to
benefit from the experience of a national group of experts
and stimulating broader discussion than many find
possible in busy local departmental meetings. 
The cases range from unusual presentation of
conditions or clusters of cancer, interpretation of
laboratory results, to the age-old ethical dilemma of the
management of families in which for example paternity
has been misattributed. An example of the latter was
presented at the meeting:  A father, known to have a
mutant high-risk cancer gene, had asked that both his
two daughters be tested for the mutant gene, even though
he knew one was not his biological daughter. He had
asked for this deception so that she would not find out
about her paternity through the lack of an offer of
predictive testing. There was general consensus that
entering into such deception was problematic and that
further facilitation of family discussion might find other
resolutions to the problem. Another presented case
queried the duty to contact at-risk relatives who had not
been informed of their high risk status by the tested
relative: A father who had tested positive for a BRCA1
mutation had declined to tell his daughters, currently in
their mid 30s, for fear of ‘upsetting’ them. The audience
was very much divided in opinion about this matter and
it was agreed that there is little in the way of professional
guidance to help decide. The ‘great debate’ at this year’s
British Society of Human Genetics (website) will debate
this very issue, in the wake of several recent publications
which demonstrated that relatives did not object to, and
indeed in some situations expected, direct contact from
the genetics service rather than an affected relative
(Newsom et al., Suthers et al., 2005). One of the other
issues discussed was the inadvertent testing of CHEK2
status in all people tested for BRCA2 (because of its
inclusion as a positive control in the commercial ARMS
kit). Many of the clinicians present were unaware of this,
and the issue came to light when a GP referral specifically
asked for CHEK2 status in the light of the Peto et al.
Lancet paper (2005) which demonstrated a high risk of
breast cancer (up to 60% lifetime risk) in first-degree
relatives of individuals with bilateral breast cancer who
were heterozygous for the del1100C allele. There was
agreement that a much larger dataset was required
before such lifetime risk figures could be used in genetic
counselling, but also a concern about using this allele
as a positive control if its risk is unclear. 
The above gives a flavour of the session, in which
several other interesting cases were discussed.
